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Dendritic cell (DC)-based vaccination effectively induces anti-tumor immunity, although
in the majority of cases this does not translate into a durable clinical response. However,
DC vaccination is characterized by a robust safety profile, making this treatment a
potential candidate for effective combination cancer immunotherapy. To explore this
possibility, understanding changes occurring in the tumor microenvironment (TME)
upon DC vaccination is required. In this line, quantitative and qualitative changes in
tumor-infiltrating T lymphocytes (TILs) induced by vaccination with autologous tumor
lysate/homogenate loaded DCs were investigated in a series of 16 patients with
metastatic melanoma. Immunohistochemistry for CD4, CD8, Foxp3, Granzyme B
(GZMB), PDL1, and HLA class I was performed in tumor biopsies collected before and
after DC vaccination. The density of each marker was quantified by automated digital
pathology analysis on whole slide images. Co-expression of markers defining functional
phenotypes, i.e., Foxp3+ regulatory CD4+ T cells (Treg) and GZMB+ cytotoxic CD8+
T cells, was assessed with sequential immunohistochemistry. A significant increase of
CD8+ TILs was found in post-vaccine biopsies of patients who were not previously
treated with immune-modulating cytokines or Ipilimumab. Interestingly, along with a
maintained tumoral HLA class I expression, after DC vaccination we observed a
significant increase of PDL1+ tumor cells, which significantly correlated with intratumoral
CD8+ T cell density. This observation might explain the lack of a significant concurrent
cytotoxic reactivation of CD8+ T cell, as measured by the numbers of GZMB+ T
cells. Altogether these findings indicate that DC vaccination exerts an important role
in sustaining or de novo inducing a T cell inflamed TME. However, the strength of the
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intratumoral T cell activation detected in post-DC therapy lesions is lessened by an
occurring phenomenon of adaptive immune resistance, yet the concomitant PDL1
up-regulation. Overall, this study sheds light on DC immunotherapy-induced TME
changes, lending the rationale for the design of smarter immune-combination therapies.
Keywords: melanoma, tumor microenvironment, T cell landscape, dendritic cell vaccine, immunomonitoring,
immunotherapy, PDL1
INTRODUCTION
According to the cancer-immunity cycle, dendritic cells (DCs)
play a fundamental role in setting off an anti-tumor specific
immune response (1). Indeed, under ideal circumstances, DCs
take up tumor antigens and promote the generation of anti-
tumor specific T cells, which ultimately infiltrate the tumor
bed and kill their target cells through cytolytic mechanisms
(i.e., perforin and granzyme B). The translation of this concept
into the clinic has led to the design of DC-based therapeutic
vaccines (2). Since their first utilization, many clinical trials have
been conducted in metastatic melanoma patients accounting
for an objective response rate of 8.5%, as reported in a
meta-analysis conducted in 1,205 advanced melanoma patients
treated with DC vaccination monotherapy (3). Similar data were
observed in our long-term follow-up series (4). Delayed-type
hypersensitivity skin test (DTH) and quantification of peripheral
antigen-specific anti-tumor T cell response with Enzyme-Linked
immunoSPOT assay and/or tetramer analysis on peripheral
blood samples, longitudinally collected during the treatment,
are commonly used to evaluate the immunogenicity of DC
vaccines. However, the reported induced tumor-specific immune
responses measured in the blood seem to only partially correlate
with efficacy (5). A higher enrichment of antigen specific T cells
inside the tumor compared to the blood has been argued as a
potential consequence of this phenomenon (6, 7). Intriguingly,
it was also suggested that the presence of an anti-tumor specific
blood response, even if weak, could serve to promote a local
inflammation in the tumor microenvironment (TME), and
intratumoral CD8+ CTL infiltration has also been envisaged as
the clinically relevant consequence of the eosinophilia found in
DC vaccinated patients and associated with positive outcome
(8). However, notwithstanding the recognized importance of
the TME, no studies have been conducted to assess whether
an in situ analysis could allow adding additional insight into
the local immune modulation occurring in DC vaccinated
patients. Besides systemic anti-tumor immunity, it becomes now
clear that the immune contexture holds precious information
endowed with clinical impact (9). In particular, the content
of intratumoral immune cells, especially CD8+ T cells, strictly
correlates with patients’ prognosis (10) across different tumor
types, melanoma included (11). Accordingly, immunological
characterization of the TME along treatment is increasingly
utilized for identifying biomarkers of response and mechanisms
of resistance to cancer immunotherapies (12, 13). Evidence
available from the literature has been primarily obtained in
patients treated with immune checkpoint inhibitors (14, 15),
and aimed at identifying biomarkers predictive of response to
therapy and finding potentially actionable synergistic targets for
improving their clinical efficacy. In this line, clinical experience
with combined anti-CTLA4 and anti-PD1 immunomodulating
antibodies has shown better efficacy in melanoma patients, but
at the expenses of more severe treatment-related toxicities. DC
immunotherapy has a robust safety profile, which makes it
an interesting good candidate for better-tolerated combination
immunotherapies. Nonetheless, an extensive characterization
of changes occurring in the TME upon DC vaccination is
currently lacking. In order to fill this gap in the literature,
we addressed by immunohistochemical (IHC) analysis the local
modulation of the T cell landscape upon DC vaccination in
a retrospective series of matched pre and post formalin-fixed
paraffin embedded (FFPE) tumor lesions collected from a series
of 16 metastatic melanoma patients treated with autologous DCs
loaded with tumor lysate/homogenate. Our data show a DC
vaccine-induced modulation of the TME, with the emergence
of changes suggestive of a T cell inflamed TME, i.e., a robust
CD8+ T cell infiltration along with the up-regulation of PDL1.
Altogether, our findings support the use of DC immunotherapy
as a TME modulating therapeutic tool, which might broaden the
effectiveness of anti-PD1/PDL1 therapies.
MATERIALS AND METHODS
Patients
In this study, we evaluated 16 patients with metastatic melanoma
enrolled in different vaccination protocols from 2000 to 2015. All
patients were given intradermally mature autologous dendritic
cell pulsed with autologous tumor lysate (ATL) or autologous
tumor homogenate (ATH) and keyhole limpet hemocyanin
(KLH). DC vaccine was administered alone (mainly in a
compassionate use program, CUP) or combined with different
conditioning therapies, e.g., low doses of temozolomide prior
to the vaccine (16) or INF alpha before leukapheresis (17) as
described inTable 1. Pre-treatment tumor samples were obtained
from tumor lesions surgically removed for the preparation of
ATL or ATH. Post-vaccine biopsies were obtained for diagnostic
and/or therapeutic purposes and were taken at least after the
fourth induction dose of the vaccine. The median time from
the pre-treatment biopsies to therapy was 3 months (0–29
months, average 6.25 months). All post-therapy lesions have
been collected on-treatment besides Pt#2, Pt#6, and Pt#10 for
whom the tumor was sampled after 18, 7, and 3 months from
the last vaccine dose, respectively. The median time from start
to biopsy was 5 months for the on-treatment samples (3–24
months, average 7 months) and 7 months for the post-treatment
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TABLE 1 | Patients’ characteristics (n= 16).
Pt#ID BRAF
status
Vax
protocol
Tumor lesion, site Months from
surgery to
first vax
Months from
baseline vax
to biopsy
harvesting
(on-treatment
or post-
treatment
biopsy)
BOR
(RECIST)/
duration
OS Objective
response of
post-vax
biopsy
DTH Previous/
following
treatments
Ratio post/
pre CD8
(cells/mm2)
PDL1 in total cells (%)
Baseline Post-vax Pre Post
1# V600E CUP Lymph
node
Lymph
node
1 17
(on-treatment)
CR/8 34 Progressing + No/CT, High
dose IL-2
1,101 7,836 3,022
2# V600E CUP Lymph
node
Subcutis 15 18
(post-treatment)
PR/68 87 Stable + BioCT/Surgery 0,913 0,726 0,402
3# V600E CUP Omentum Stomach 2 24
(on-treatment)
SD/50 108+ Stable + BioCT/Surgery,RT 0,823 16,750 6,185
4# WT Tem Peritoneum Subcutis 2 4 (on-treatment) SD/4 16 Progressing + CT, Ipi/RT 0,173 4,744 4,793
5# na Tem Subcutis Omentum 1 4
(on-treatment)
SD/10 45 Progressing + RT/Ipi 1,338 11,130 24,700
6# V600E Tem Lung Skin 3 7 (on-treatment) SD/9 62 Progressing + BioCT/low
doses IL-2, Ipi
0,521 0.9748 9,203
7# V600E CUP Subcutis Subcutis 10 5 (post-
treatment)
SD/7 22 Progressing + CT*/Ipi 0,560 0,826 7,519
8# WT CUP Jejunum Adrenal
gland
29 4
(on-treatment)
PR/57 87+ Stable ++ CT/Ipi, CT 3,010 0,000 33,639
9# V600E CUP Lymph
node
Subcutis 3 5
(on-treatment)
SD/6 23 Progressing + No/
Ipi,vemurafenib,
Tem
4,039 0,602 6,530
10# V600E CUP Subcutis Lymph
node
12 3
(post-treatment)
SD/5 18 Progressing + Biot/RT 0,110 8,771 na
11# WT CUP Subcutis Subcutis 3 9
(on-treatment)
SD/5 27 Progressing + No/CT, Ipi 1,051 1,255 13,999
12# WT CUP Subcutis Subcutis 8 4 (on-treatment) PDU 13 Progressing - Biot/No 1,355 na na
13# WT Vax+INFα Subcutis Subcutis 5 3
(on-treatment)
PD 11 Progressing + No/Ipi 2,260 1,677 8,201
14# WT Vax+INFα Lymph
node
Subcutis 0 3
(on-treatment)
PD 7 Progressing + No/Ipi 5,013 2,465 11,765
15# WT Vax only Subcutis Brain 4 6 (on-treatment) SD/5 8 Progressing + CT, Ipi/No 1,080 2,379 0,893
16# V600E CUP Adrenal
gland
Skin 2 5
(on-treatment)
PD 19 Progressing + No/Ipi,
vemurafenib,
BioCT,
pembro
5,097 1,709 14,279
Vax, dendritic cell vaccination; DTH, delayed-type hypersensitivity; WT, wild type; CUP, compassionate use program; CT, chemotherapy; CT*, chemotherapy third line; RT, radiotherapy; Tem, temozolomide; IFNα, interferon alpha; IL-2,
interleukine 2; Biot, low doses of cytokines (IL-2 and/or IFNα); BioCT, cytokine+chemotherapy; Ipi, ipilimumab; pembro, pembrolizumab. Naïve/CT/RT patients are highlighted in bold. UPt#12 was treated beyond progression after
surgical removal of the progressing lesion.
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samples (3–18 months, average 9.33 months). Clinical response
was defined according to RECIST 1.1 criteria (18) and surgically
removed post-vaccine tumor lesions were classified as regressing
if changes in their longest diameter were ≥–30% compared with
the baseline, stable if changes were comprised between −30 and
+20%, and progressing if ≥+20% (Table 1). All patients gave
their informed consent to the study, which was conducted in
accordance with the Declaration of Helsinki following a protocol
approved by the local Institutional Review Board.
Generation and Administration of DCs
DCs were prepared following Good Manufacturing Practice
(GMP) guidelines and according to Ridolfi et al. (16). Briefly,
monocytes obtained by adherence of the leukapheresis product
on culture flasks were cultured in CellGro DC medium
supplemented with interleukin 4 (IL-4, Cell Genix) and
granulocyte-macrophage colony stimulating factor (GM-CSF,
Cell Genix) for 7 days. On day 6, 90% of the DC culture was
pulsed with ATL or ATH (100 mg/ml), while the remaining 10%
was pulsed with KLH (50 mg/ml). On day 7, the culture medium
was discarded and immature DCs were cultured for further
2 days with a maturation cocktail comprising the following
cytokines: TNFα, IL-1β, IL-6 (Cell Genix), and PGE2 (Pfizer).
On day 9, mature dendritic cells (median 107, range 2.2–20.8
× 106) were recovered, washed, suspended in sterile saline
solution and immediately injected. As part of our standard
release criteria, before administration, DCs were checked for
safety (sterility, mycoplasma, endotoxin), vitality, purity, and
maturation phenotype. Purity was always reported to be >60%
(average 63, 59%). The maturation phenotype of the infused DCs
was confirmed by flow cytometry using the following markers:
HLADR (accepted cut-off value ≥60%, average= 85, 8%), CD80
(accepted cut-off value≥50%, average= 83, 4%), CD83 (accepted
cut-off value ≥40%, average= 74,9%), and CD86 (accepted cut-
off value ≥60%, average= 78,8%). Patients were given 107 DCs
intradermally at the base of the thigh or groin every 2 weeks
for 4 cycles, followed by monthly doses until progression,
worsening of clinical conditions (ECOG performance status >
2), or autologous tumor lysate shortage. Patients who ran out
of tumor lysate, but had additional surgically removable tumor
lesions, were retreated utilizing tumor lysate obtained from newly
removed lesions. Antitumor immune response to the DC vaccine
was evaluated with Delayed-Type Hypersensitivity (DTH) test
as follows: serial concentrations (100, 50, 20, 10, and 5 µg) of
autologous tumor lysate and KLH were intradermally injected
into the forearms of patients and erythema and induration were
recorded after at least 24 h. DTH was considered as positive if the
area of erythema and/or induration measured at least 5mm at
any antigen concentration.
Standard and Sequential
Immunohistochemistry (IHC)
IHC stainings were performed on 4µm FFPE tissue sections.
Briefly, after deparaffinization in xylene and rehydration in
graded ethanol, sections were washed in phosphate-buffered
saline (PBS). After an antigen retrieval step, sections were
incubated with the primary antibody (see Table 2 for details).
Reactions carried out on Ventana BenchMark automated slide
stainer were performed according to manufacturer’s instructions.
The sections were then kept for 15min at room temperature
(RT) before further PBS washing and immunostained with a
standard streptavidin-biotin-peroxidase procedure, followed by a
3,3-diaminobenzidine (DAB) color reaction and counterstaining
with hematoxylin. Experimental conditions and list of primary
antibodies clones are reported in Table 2. All the antibody
conditions were validated on tissue microarrays (TMAs)
containing different positive control tissues. For sequential
IHC, a non-biotin Poly HRP conjugate system followed by
aminoethyl carbazole (AEC) substrate reaction was used instead
of DAB. For consecutive cycles of staining, a chromogen
destaining step (in alcohol) and a stripping step (in citrate
buffer) were applied according to a previously published protocol
(19). Reproducibility of the staining along increasing cycles of
staining/destaining was checked for each marker utilized in
sequential staining (Supplementary Figures 1, 2).
Image Acquisition
High-resolution whole slide images (40x and 20x magnifications)
(WSI) of IHC stained slides were acquired using the Aperio
CS2 slide scanner (Leica Biosystems Nussloch GmbH) or
the MicroVisioneer Manual WSI system (MicroVisioneer,
20x magnification).
Software Assisted Quantification of Single
IHC Stains
Digital pathology analysis was performed on WSIs with QuPath,
an open source image analysis software (20). Quantification
of IHC stains was supervised by an expert Pathologist (MG):
tumor areas, non-tumoral stroma, and necrotic areas were
separately annotated, and artifacts (e.g., tissue folding) deselected
and excluded from the analysis. Quantification of marker
positive cells was performed in tumor areas, excluding non-
tumoral stroma and necrosis. In the analysis of the lymph
node metastasis (n= 5) attention was paid to only count for
tumor-infiltrating T lymphocytes, excluding those associated to
the lymph node tissues. The density of positive cells (i.e., the
number of positive cells per mm2) was calculated for CD4, CD8,
FoxP3 and Granzyme B; the percentage of positive cells on
the total was instead calculated for PDL1. Detection of positive
cells was performed using QuPath’s Simple Tissue Detection and
Positive Cell Detection methods. Briefly, bright-field images were
analyzed using the setup parameter optical density sum to avoid
nuclei detection loss in samples showing weak haematoxylin
counterstain. Alternatively, theHematoxylin OD setup parameter
was preferentially used to avoid overestimating the total cell
number (due to background artifacts). For nuclear markers
detection (e.g., Foxp3) the AEC or DAB signal was assessed using
the command Nucleus DAB OD mean ormax, whereas Cell DAB
OD mean or Cytoplasm DAB OD mean commands were applied
for surface or cytoplasmatic markers detection, respectively.
Otherwise, when active the Optical density sum parameter, the
intensity of the cell and cytoplasmatic signal was assessed in
the cell nuclei, since this parameter tends to include in the
nucleus the AEC or DAB signal that comes from the membrane
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TABLE 2 | Details of IHC antibodies.
Antibody Clone Isotype
/host
Supplier
cat#
Dilution/Ab
reaction
Antigen retrieval Ab diluent Position in
sequential
IHC/AEC
reaction time
CD45 2B11+ PD7/26 IgG1/Mouse
monoclonal
Dako
Cat#M0701
1:50/1 h RT EDTA (Ph8) water
bath 100◦C,
40min
PBS + 1%BSA +
0,02% sodium
azide
2◦/30 min
CD4 EPR6855 IgG/rabbit
monoclonal
Abcam
Cat#ab133616
1:100/1 h RT EDTA (Ph8)
water bath
100◦C, 40 min
PBS + 1%BSA +
0,02% sodium
azide
4◦/30 min
4B12 IgG1/mouse
monoclonal
Dako
Cat#M7310
1:100/1 h RT TRIS EDTA (Ph9)
water bath
98.5◦C, 20min
Ventana Antibody
Diluent
Cat#251-018
CD8 4B11 IgG2b/mouse
monoclonal
Thermo
scientific
Cat#MA1-80231
1:40/1 h RT EDTA (Ph8)
water bath
100◦C, 40 min
PBS+1%BSA+
0,02% sodium
azide
4◦/30 min
4B11 IgG2b/mouse
monoclonal
Novocastra
Cat#NCL-L-
CD84B11
1:100/1 h RT TRIS EDTA (Ph9)
water bath
98.5◦C, 20min
Ventana Antibody
Diluent
Cat#251-018
Foxp3 SP97 IgG/rabbit
monoclonal
Thermo
Scientific
Cat#MA5-16365
1:100/1 h RT EDTA (Ph8)
water bath
100◦C, 40 min
PBS + 1%BSA +
0,02% sodium
azide
2◦/30 min
236A/E7 IgG1/mouse
monoclonal
Abcam
Cat#ab20034
1:100/1 h RT Citrate buffer (Ph6)
water bath
98.5◦C, 20min
Ventana antibody
diluent
Cat#251-018
Granzyme B GrB-7 IgG2a/mouse
monoclonal
Merk/Millipore
Cat#MAB3070
1:20/1 h RT EDTA (Ph8)
water bath
100◦C, 40 min
Ventana
Antibody Diluent
Cat#251-018
1◦/30 min
1:20/1 h RT Citrate buffer (Ph6)
water bath
98.5◦C, 20min
Ventana Antibody
Diluent
Cat#251-018
PDL1 SP142 IgG/rabbit
monoclonal
Spring Bioscience
Cat#M4424
1:100/1 h RT EDTA (Ph8)
water bath
100◦C, 40 min
PBS + 1%BSA +
0,02% sodium
azide
1◦/30 min
1:40/1 h RT Cell conditioning
solution (CC1)
ventana BenchMark
Cat#950-124
Ventana antibody
diluent
Cat#251-018
Antibodies and conditions applied in the optimized sequential IHC protocol are indicated in bold.
or cytoplasm. Parameters were set-up for each slide on at least
three fields selected for optimal or suboptimal staining (e.g., high
melanin content) to obtain the better parameters combination
for total cells and positive cells enumeration. Then, the number
of positive cells detected per area was used to calculate the
average number of positive cells per mm2, and these results
exported along with mark-up images showing the detected cells
for visual verification.
Processing of Multiplex/Sequential IHC
Images
To perform co-localization analyses, we designed Data Science
for Health (DS4H) Image Alignment, a user-friendly tool freely
provided as an ImageJ/Fiji plugin. With DS4H Image Alignment,
multiplex/sequential IHC images can be easily co-registered
by defining with a few clicks some well-visible reference
marks. The implemented least-squares method automatically
approximates the solution of the mathematical over-determined
system, so to define the registration matrix then used to
align the different images (21, 22). It also considers rotations
and scale changes in case the staining/destaining/stripping
steps generated a tissue dilation/shrink (23). Finally, it
provides an iterative subroutine for a fine alignment, to
easily reach a very good image co-registration quality. Practically
speaking, the sequential IHC images considered in this work
have been: (a) imported into Fiji; (b) cropped to extract
corresponding, significant Regions Of Interest (ROI); (c)
aligned with DS4H Image Alignment; (d) separated into single
channels using the H AEC option of the ImageJ/Fiji Color
Deconvolution tool (24); then, (e) the AEC channels have
been re-aligned into a z-stack for final comparisons. DS4H
Image Alignment has been implemented in Java as a plugin
for ImageJ/Fiji. It works with “.svs” files, but also all the
medical imaging formats included in Bio-Formats (25, 26).
DS4H Image Alignment version 1.0 is freely available at:
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www.filippopiccinini.it/DS4H-IA.html, together with a sample
dataset and a video tutorial.
Statistical Analysis
Statistical analysis was performed usingGraphPad Prism (version
6, Jolla, CA, USA). A non-parametric two-tailed Wilcoxon
signed-rank test was used to evaluate differences in the
distribution of the number of cells positive for a given marker
per square millimeter between pre- and post-vaccine biopsies.
Correlations of PDL1 expression with the immune infiltrate were
analyzed by Spearman’s rank correlation coefficient. A p-value of
<0.05 was considered as statistically significant.
RESULTS
Patients and Clinical Outcomes
Based on the availability of both pre- and post-vaccine
tumor biopsies, 21 patients treated with DC vaccination at
Morgagni Hospital (Forlì, FC, Italy) and IRCCS-IRST (Meldola,
FC, Italy) between 2000 and December 2015 were initially
selected: in five cases pre-treatment or post-treatment biopsies
were not evaluable (mainly for insufficient tumor tissue left).
Detailed information on patient characteristics and vaccine
administration is provided in Table 1. All patients, except one
(Pt#12), were immunoresponsive to the vaccine, as shown by
positivity to DTH tests performed after at least four induction
immunizations. Patients’ median age at study entry was 51 years
(range 31–73) and both genders were equally represented (nine
males and seven females). In 11 out of the 16 cases indagated the
sites of tumor biopsies taken before and after vaccination were
of the same type, i.e., soft tissue/nodal or visceral, according to
the classification provided in Bartlett et al. (27), thus avoiding
any statistically significant imbalance in the level of CD8
expression in the selected pre-treatment sample cohorts. Best
overall response (BOR) to the treatment per RECIST 1.1 criteria
was complete response (CR) in one patient, partial response
(PR) in two patients, stable disease (SD) in nine patients,
while the remaining four patients showed progressive disease
(PD) at the first radiological tumor assessment. Retrospective
evaluation confirmed that Pt#12, Pt#13, Pt#14, and Pt#16 were
all confirmed PD even when immune-related response criteria
were applied. Median duration of response was 7.5 months
(range 4–68 months). Median overall survival was 22 months
(range 7–108 months). Six patients were given DC vaccine
as a first line therapy, whereas the remaining had received
at least one therapy line before (chemotherapy, radiotherapy,
biochemotherapy or immunotherapy).
Increase of CD8+ T Cell Characterizes
Post-DC Vaccine Tumor Lesions of Naïve
and Chemo/Radiotherapy Treated
Melanoma Patients
To gain insight into the intratumoral T cell landscape of DC
vaccinated patients, quantification of CD8 and CD4 positive
cells was performed on matched pre and post FFPE tumor
biopsies. Globally, the amount of intratumoral CD8+ T cells
increased in post-treatment tumor biopsies compared with
pre-treatment ones, although this change did not reach statistical
significance (mean± SEM 597.9± 132.7 vs. 731.5± 159.0
CD8+ cells/mm2 in pre-treatment and post-treatment biopsies,
respectively; p= 0.2114; Figure 1A). In six cases the content
of intratumoral CD8+ T cells decreased after treatment:
interestingly, one of these patients (Pt#4) started DC vaccination
after failure on Ipilimumab and showed a very high pre-
treatment level of intratumoral CD8+ T cells (1,068.927
cells/mm2 vs. 185.006 cells/mm2, in pre- vs. post-vaccine lesion,
respectively; Table 1, Supplementary Table 1). Moreover, four
out of the five remaining patients had previously received
cytokines either in combination with chemotherapy (BiotCT)
or as low doses IFNalpha and IL-2 (Biot), and showed higher
levels of pre-treatment levels CD8+ T cells as well (Table 1,
Supplementary Table 1). Along this line, patients were stratified
into two separate groups: 1) naïve/CT/RT, comprising patients
who received the vaccine as a first line therapy (n= 6), after
chemo- (n= 2), or radiotherapy (n= 1); 2) immuno_treated,
accounting for all patients (n= 7) previously treated with
immunomodulating cytokines or anti-CTLA4 (Ipilimumab,
Ipi). Intriguingly, a selective significant increase of tumor-
associated CD8+ T cells in post- vs. pre-vaccine samples was
observed in the naïve/CT/RT group (mean± SEM 533.2± 201.7
vs. 878.6± 220.3 CD8+ cells/mm2 in pre-treatment and
post-treatment biopsies, respectively; p= 0.0195, Figure 1B,
Supplementary Table 1) compared to the immuno_treated
one (mean± SEM 681.0± 1,649.7 vs. 542.4± 224.9 CD8+
cells/mm2 in pre-treatment and post-treatment biopsies,
respectively; p= 0.2969; Figure 1B, Supplementary Table 1).
Figure 1C shows the QuPath-generated mark-up WSI of CD8
stain in the pre and post-vaccine lesions of Pt#16 displaying a
remarkable increase in tumor-associated CD8+ T cells (269,037
vs. 1,371,354 cells/mm2, in pre- and post-vaccine, respectively).
Of note, while lesions analyzed upon DC vaccination were
mainly resected during treatment (on-treatment samples),
as for all those of the naïve/CT/RT group, three out of seven
samples belonging to the immuno_treated group (identified
with square within the graphs) represent lesions sampled after
the last vaccine dose (post-treatment samples). To reinforce
our results and data interpretation we confirmed the absence
of statistically significant difference in the post/pre CD8
ratio between these post-treatment samples (n= 3) and those
harvested on-treatment (n= 4) (Mean± SEM; 0.5147± 0.2318
and 0.8578± 0.2528, respectively).
No significant change in the number of intratumoral CD4+
T cells upon DC vaccination was observed in any of the
patient groups (Figures 1D,E), speaking in favor of a specific DC
vaccine-mediated modulation of the CD8+ Cytotoxic T Cell arm
of the adaptive immune system.
CD8+ T Cell Infiltration Is Paralleled by a
Concurrent Increase of PDL1 Expression in
Tumor Cells
Anti-tumor T cell activity requires antigenic presentation in
the context of human leukocyte antigen (HLA) molecule and
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FIGURE 1 | Quantitative analysis of intratumoral CD8+ and CD4+ T cells of serial tumor biopsies from DC vaccine treated patients. The number of intratumoral CD8+
T cells per mm2 in matched pre- and post- treatment samples is plotted in graphs. Graph showing all patients (n=16, p=0.2144) (A). Right and left graphs showing
naïve/CT/RT (n= 9, *p= 0.0195), and immuno_treated (n=7, p= 0.2969), respectively (B). Whole slide images (WSI) of CD8 staining in the pre- and post-vaccine
lesions of one representative patient (Pt#16). Scale bars 1 and 2mm for the left and the right WSI panel, respectively. Higher magnification images for the mark-up
CD8 stain in pre- and post- treatment samples are shown. Scale bars, 100µm (C). The number of intratumoral CD4+ T cells per mm2 in matched pre- and post-
treatment samples is plotted in graphs. Graph showing all patients (n=9, p= 0.4258) (D). Right and Left graphs showing naïve/CT/RT (n= 5, p > 0.9999) and
immune_treated (n= 4, p=0.1250), respectively (E). CR and PR Patients are displayed in green, SD in black, and PD in red. Open circles denote on-treatment
samples, open triangles post-treatment ones. Statistical comparisons are based on the non-parametric two-tailed Wilcoxon signed-rank test. Only values statistically
significant are reported: *p < 0.05.
loss or inability to up-regulate HLA class I expression is
a common mechanism of tumor immune escape. Another
crucial way tumor cells avoid immune-mediated killing is
the up-regulation of the immune checkpoint molecule PDL1.
Therefore, we assessed whether the increase in intratumoral
CD8+ T cells after DC vaccination was associated with relevant
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changes in the expression of HLA class I by melanoma cells
or in the pattern of expression of PDL1. No difference was
found in HLA class I expression between pre and post-DC
therapy lesions (Figure 2A), indicating that loss/downregulation
of HLA class I molecules is unlikely involved in immune
escape after DC vaccine in our series. Intriguingly, when
PDL1 expression was evaluated, a significant increase in the
number of PDL1+ tumor cells was detected in post-vaccination
tumor biopsies (11 out of 14 assessable paired biopsies,
mean± SEM 3.721± 1.316 vs. 10.37± 2.456 PDL1% in pre-
treatment and post-treatment biopsies, respectively; p= 0.0353)
(Figure 2B). A representative case is shown in Figure 2C.
Of note, we found that this up-regulation was stronger in
the naïve/CT/RT cohort (n= 9, mean± SEM 3.056± 1.268 vs.
13.74± 3.242 PDL1% in pre-treatment and post-treatment
biopsies, respectively; p= 0.0078), while it did not reach
statistically significance in the immune_treated one (n= 5,
mean± SEM 4,920± 3,068 vs. 4,295± 1,653 PDL1% in pre-
treatment and post-treatment biopsies, respectively; p= 0.6250),
suggesting a positive correlation with the observed higher density
of intratumoral CD8+ T cell infiltrate (Figure 2D). Indeed,
Spearman’s correlation analysis showed a significant positive
correlation between the density of CD8+ T cells and the
percentage of PDL1+ cells (Spearman r= 0.4948, p= 0.0074;
Figure 2E). Mark-up WSI overview of PDL1 stain for Pt#16
(Supplementary Figure 3A) shows the spatial distribution of
PDL1 expression in post-therapy biopsy and clearly highlights
that the enriched expression of PDL1 was topographically
associated with the CD8+ T cell infiltrated areas (Figure 1B).
Sequential staining on the same tissue section of CD45 and
PDL1 allowed discerning its relative expression on tumor
cells and immune cells. Pseudo-fluorescence double images
(Supplementary Figure 3B) confirmed that PDL1 was expressed
almost exclusively in tumor cells and underscore the proximity
of CD45+ immune cells to that of PDL1+ tumoral cells, stressing
the inducible nature of PDL1 expression.
Intratumoral PDL1 Counteracts Cytotoxic
Activation of Intratumoral CD8+ T Cells
To further understand the activation extent of tumor-infiltrating
CD8+ T cells we examined paired pre and post DC vaccine
tumor samples for the presence of Granzyme B (GZMB), a
key functional marker of effector cytotoxic CD8+ lymphocytes.
Thirteen cases were assessable for the GZMB staining. Co-
expression of GZMB and CD8 was assessed by sequential IHC,
and confirmed that a considerable fraction of CD8+ T cells were
activated cytotoxic CD8+ lymphocytes, rather than potentially
activated GZMB+CD8− natural killer cells. A representative
image of the reconstructed double pseudo-fluorescence image is
shown in Figure 3A (Pt#16). Moreover, the tight association of
apoptotic or necrotic tumor cells with CD8+ TILs together with
the polarization of the cytotoxic granules toward melanoma cells
(data not shown), strongly support the functional relevance of the
defined phenotype. The GZMB:CD8 ratio was used to define the
effective fraction of intratumoral cytotoxic T cells. Unexpectedly,
no significant change in the amount of GZMB+ cells was found
between pre- and post-treatment tumor biopsies (mean± SEM
118.3± 47.68 vs. 137.2± 51.98 GZMB+ cells/mm2 in pre-
treatment and post-treatment biopsies, respectively; p= 0.5830;
Figure 3B). In addition, the observed increase in the number of
CD8+ cells in the naïve/CT/RT group was not paralleled by a
concurrent increase in GZMB-expressing cells, suggesting that
cytotoxic activation of vaccine-induced intratumoral CD8+ T
cells may have been hampered by the up-regulation of PDL1 on
tumor cells. Supporting this hypothesis, we found a significant
inverse correlation (Spearman r=−0.8667, p= 0.0045) between
the GZMB:CD8 ratio and the percentage of PDL1+ cells
(Figure 3C). An additional crucial mechanism involved in
impairing the CD8 effector program is the presence in the
TME of immune suppressive cells, like Foxp3+ regulatory
T cells (Tregs). In this respect, we evaluated the density of
intratumoral Foxp3+ cells in our series. Sequential IHC stainings
(Figure 3D) showed that Foxp3 was expressed exclusively in the
CD4+ compartment, thus excluding any association with CD8
potentially accounting for early effector CD8+ T lymphocytes
(28) and confirming that in our samples Foxp3+ cells were for
the large majority Tregs. Due to the shortage of tumor material,
four samples could not be assessed (Supplementary Table 1).
In the remaining 12 patients we observed a trend (7 out of
12 cases) toward a decrease in the number of Foxp3+ cells
(mean± SEM 163.7± 101.7 vs. 110.5± 44.56 Foxp3+ cells/mm2
in pre-treatment and post-treatment biopsies, respectively;
p= 0.7344, Figure 3E). Similarly, no significant increase of this
immunosuppressive population was observed in any of the
analyzed groups (Figure 3E), indicating that this mechanism is
unlikely involved in decreasing cytotoxic activation of CD8+
effector cells.
DISCUSSION
It is widely recognized that DC vaccination as monotherapy
has a limited clinical efficacy, particularly in heavily pretreated
Patients. However, DC vaccines are very well-tolerated, and in
the actual clinical scenario they could have a role in combination
immunotherapy with immune checkpoint inhibitors. Nowadays,
their interaction is still poorly understood and clinical trials
are needed to identify the best sequential or combination
regimen. In this respect, immune monitoring within the TME
has been fundamental for the discovery of mechanisms of
response and resistance to treatment, as well as instrumental
for the design of combination regimens to enhance anti-
tumor immunity and clinical responses. Accordingly, this study
describes the qualitative and quantitative changes of immune cell
subpopulations occurring in the TME in a cohort of metastatic
melanoma patients treated with autologous tumor lysate loaded
mature DCs for whom matched pre and post-therapy material
was available from our Institutional repository. Likewise, Gross
et al. attempted to score CD3+ lymphocytic infiltration upon DC
vaccination, but the analysis was conducted on pre-vaccination
metastases in 17 patients and post-vaccination metastases in 17
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FIGURE 2 | HLA class I and PDL1 expression in serial tumor biopsies from DC vaccine treated patients. The pattern of HLA class I expression by melanoma cells is
shown in matched pre- and post-therapy lesions for one representative patient (Pt#10). Scale bars, 250µm (A). Differences in intratumoral PDL1 expression are
illustrated in the graph as the percentage of PDL1 expressing cells on the total cell number (n=14, *p= 0.0353) (B). A representative example of the staining is shown
(Pt#13). Scale bars, 100µm (C). PDL1 expression distribution in matched samples within the naïve/CT/RT cohort and the immuno_treated cohort is reported in right
and left graphs (n= 9, **p=0.0078 and n= 5, p= 0.6250), respectively. CR and PR Patients are displayed in green, SD in black, and PD in red. Open circles denote
on-treatment samples, open triangles post-treatment ones (D). A positive correlation was found between CD8 and PDL1 expression (Spearman r=0.4948,
p=0.0074) (E). Statistical comparisons are based on the non-parametric two-tailed Wilcoxon signed-rank test. Only values statistically significant are reported:
*p < 0.05 and **p < 0.01.
patients, with paired samples available in only seven patients
(5). However, albeit limited by the number of samples, a higher
lymphocytes score was recorded in post-vaccine tumor samples
compared to pre-vaccine ones. Additionally, a higher immune
infiltration following DC vaccination was also highlighted in
glioblastoma multiforme, particularly including a CD8+ T cell
population (29). To the best of our knowledge, our study
represents the largest retrospective analysis of a unique cohort
of matched pre and post samples from metastatic melanoma
patients treated with an autologous DC vaccine. Remarkably,
our quantitative analysis was conducted on WSI, rather than
selected areas, and using resected surgical specimens, which
are more representative of the entire TME compared to core
needle biopsies or frequently used tissue microarrays. Our
data showed that DC vaccination increases the number of
intratumoral CD8+ T cells, although the differences observed
between pre-treatment and post-treatment biopsies were not
statistically significant in the whole series. However, when
patients were analyzed according to the type of treatment
they received before DC vaccination some differences emerged.
In particular, patients who previously failed immunological
treatments did not show significant changes in the density of
intratumoral CD8+ T cells, suggesting that the DC vaccine-
driven effects on the TME might have been hampered by
different mechanisms of immune escape that have led to
the failure of previous immunotherapy. Indeed, it has been
extensively reported that in the metastatic disease setting, one
of the major obstacles to DC vaccine efficacy is represented
by the occurrence of multiple mechanisms of tumor-induced
immunosuppression (30). Accordingly, it can be assumed that,
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FIGURE 3 | Analysis of the functional phenotype of intratumoral CD8+ and CD4+ T cells. The co-expression of GZMB and CD8 was evaluated by sequential IHC.
AEC color signals were extracted from each digitized single-marker image by color deconvolution, followed by pseudo-coloring. A representative image is shown
(Pt#16). Nuclei (blue), GZMB (red), CD8 (green). Scale bars, 100µm (A). The GZMB expression between matched pre- and post-therapy samples, either in the total
patient cohort or in any of the defined patient groups is illustrated in graphs (all patients n=14 p= 0.5830, naïve/CT/RT n= 9 p=0.2500, immuno_treated n= 5
p=0.4375) (B). Correlation between the GZMB ÷ CD8 ratio and the percentage of PDL1 over total cells in the naïve/CT/RT patient cohort (Spearman r=−0.8667,
**p= 0.0045) (C). FFPE pre-therapy sections were analyzed by multiplex IHC. Results from a representative patient (Pt#3) are shown. Nuclei (blue), GZMB (yellow),
CD8 (gray), CD4 (green), and Foxp3 (red). Scale bars, 100µm (D). Changes in the expression of Foxp3 marker in matched pre- and post-therapy lesions are shown in
graphs for all patients (n= 12, p= 0.2334) as well as for the two defined patient sub-groups (naïve/CT/RT n= 9, p= 0.7334, immuno_treated n=3, p= 0.2500) (E).
CR and PR Patients are displayed in green, SD in black, and PD in red. Open circles denote on-treatment samples, open triangles post-treatment ones. Statistical
comparisons are based on the non-parametric two-tailed Wilcoxon signed-rank test. Only values statistically significant are reported.
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upon failure to the previous immune-based treatments, patients
belonging to the immuno_treated group could have developed
strong immunosuppression, which negatively affects the ability
of DC vaccination to increase intratumoral CD8+ T cells, as
instead observed in the naïve/CT/RT group. Besides not being
forms of immunotherapy, we know that chemotherapy (CT)
and radiotherapy (RT) might exert immune-modulating effects
(31, 32). In light of this, while in all the naïve patients (n= 6)
we observed a marked CD8+ T cell up-regulation compared
to baseline treatment (Supplementary Table 1), one CT-treated
patient (Pt#7) did not actually display a CD8+ T cell increase,
thus behaving more similar to the immune_treated group. The
second striking effect we observed after DC vaccination was
the marked up-regulation of PDL1 expression. Similar to what
previously described (33) and in accordance to its inducible
profile, we found that the intratumoral PDL1 expression was a
reflection of the endogenous CD8+ T cell abundance, as shown
by the positive correlation between the percentages of PDL1+
cells and CD8+ T cell density. Again, WSI distribution analyses
showed a strictly related spatial distribution of PDL1+ cells
and CD8+ TILs. Multiplex IHC for CD45 and PDL1 further
confirmed that PDL1 was largely expressed in CD45− tumor cells
in close proximity to CD45+ immune cells. Our data are also
consistent with the hypothesis that cytotoxic activation of CD8+
T cells recruited in the TME after DC vaccination can be strongly
inhibited by PDL1 concurrently induced in tumor cells, as
suggested by the significant negative correlation between PDL1+
cells and the GZMB:CD8 ratio. A comprehensive evaluation
of the tolerability and clinical efficacy of our DC vaccination
protocols has been already provided (4), and an association of the
immune contexture with the clinical activity was out of the scope
of the current study. Interestingly, in three out of the four truly
progressing patients (Pt#13, Pt#14, and Pt#16), the strong rise of
CD8+ T cells in the tumor microenvironment was matched by
an increased expression of the PDL1 inhibitory molecule, thus
suggesting an immune escape–associated progression. Although
the underlined PDL1 pattern partially explains the limited
functionality of intratumoral T cells, we recognize that changes
in the immune signature observed did not fully correlate with
the clinical outcome of the vaccination. In addition, the lack
of correlation between Foxp3+ cell densities and cytotoxic
activation of CD8+ T cells further reinforces the role of
PD1/PDL1 axis activation in suppressing DC vaccine-induced
cytotoxic immune response. Additional studies, albeit hampered
by the limited accessibility to this type of samples, will be
needed to confirm our findings and potentially also shed light on
other markers/immune populations. Indeed, we do not exclude
that other phenomena, such as the variation in the number of
intratumoral Foxp3+ cells, be involved in the limited clinical
efficacy of DC vaccination, and could have been detected if the
analysis was conducted on a greater number of cases. DCs by
nature are crucial for immunosurveillance and thus more likely
for the de novo induction of anti-tumor immunity, although
DC vaccination could hardly overcome profound tumor-induced
immunosuppression. Accordingly, DC vaccinationmonotherapy
is increasingly utilized in the adjuvant setting (34, 35).
Conversely, it has been shown that pre-existing spontaneous
immune response largely directed against neoantigens are
frequently associated with a “hot” (i.e., T cell inflamed) TME,
characterized by high levels of CD8+ T cells together with
immune-mediated adaptive PDL1 up-regulation. Of note, T
cell inflamed tumors more likely respond to therapeutic PD-
1 blockade (36). Interestingly, a recent phase 3 clinical trial
with the combination of the anti-CTLA4 monoclonal antibody
ipilimumab and the anti-PD1 nivolumab inmetastatic melanoma
showed an advantage, both in terms of PFS and OS, of the
combination over nivolumab alone in patients with PDL1
negative tumors (37), but at the expenses of much higher toxicity.
In this line, synergism might be observed between PD1/PDL1
blockade and treatments up-regulating PDL1 expression in the
TME in patients carrying PDL1 negative melanomas. On these
grounds, the very favorable toxicity profile, together with its
ability to turn “cold” into “hot” tumors, define DC vaccination
as a promising candidate for combination with inhibitors of the
PD1/PDL1 immune checkpoint.
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